Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects
Loading...
Issue Date
2004-01
Authors
Allie, Edward C ++
Kane, Michael P.
Busch, Robert S.
Bakst, Gary
Hamilton, Robert A.
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Almost two-thirds of the adult American population is overweight. Obesity is associated with a higher incidence of hypertension, dyslipidemia, diabetes mellitus and coronary artery disease. Orlistat, a gastrointestinal lipase inhibitor, provides an option for weight loss management in addition to diet and exercise. This study assessed the metabolic response of patients with type 2 diabetes mellitus to orlistat. Forty-one patients with type 2 diabetes who received orlistat in a private endocrinology practice were identified by a computer-assisted retrospective chart review. Orlistat's effects on weight, blood pressure, lipid parameters, hemoglobin A1C (HbA1C), and concurrent medication use were identified. Analysis of the 23 patients who remained on the drug for a minimum of 3 months revealed statistically significant reductions in patient weight, body mass index (BMI), total cholesterol, HDL cholesterol, and LDL cholesterol levels. For patients with type 2 diabetes who were able to tolerate the drug, orlistat was associated with improvement in several cardiovascular risk factors.
Citation
Allie EC, Kane MP, Busch RS, Bakst G, Hamilton RA. Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects. Hospital Pharmacy. 2004;39(1):37-42. doi:10.1177/001857870403900114
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).